{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:54:04Z","timestamp":1795042444710,"version":"4.10.2"},"reference-count":173,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>\n                    Vaginitis is the presenting symptom at millions of office visits each year in the United States. Although treatment of sporadic cases is often straightforward, recurrent cases present both diagnostic and treatment challenges. Molecular diagnostic tests are likely superior to in-office microscopy for most clinicians and most cases. In both recurrent bacterial vaginosis and recurrent vulvovaginal candidiasis, national treatment guidelines recommend an extended treatment duration with one of the first-line agents. In cases in which such treatment is not successful, vaginal boric acid is likely the cheapest and easiest alternative option. New antifungal medications offer additional but limited treatment options. Probiotics are not recommended for prevention of vulvovaginal candidiasis; however, vaginal products containing\n                    <jats:italic toggle=\"yes\">Lactobacillus crispatus<\/jats:italic>\n                    may have promise for recurrent bacterial vaginosis. Trichomoniasis should be treated with a 1-week course of metronidazole; this is the only sexually transmitted infection for which treatment recommendations vary by sex. In cases in which patients do not respond to initial treatment, the diagnosis should be reconsidered, and other potential causes such as desquamative inflammatory vaginitis, genitourinary syndrome of menopause, or vulvodynia should be considered.\n                  <\/jats:p>","DOI":"10.1097\/aog.0000000000005673","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:50:31Z","timestamp":1742403031000},"page":"765-781","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Assessment and Treatment of Vaginitis"],"prefix":"10.1097","volume":"144","author":[{"given":"Caroline M.","family":"Mitchell","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, and the Vulvovaginal Disorders Program, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"R1-20260826","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/itx.0000000000000045","article-title":"Prediction of ambulatory visits for itching diseases using Google Trends data","volume":"6","author":"Muddasani","year":"2021","journal-title":"Itch"},{"key":"R2-20260826","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/pop.2021.0143","article-title":"Diagnostic testing of vaginitis: improving the value of care","volume":"24","author":"Kong","year":"2021","journal-title":"Popul Health Manag"},{"key":"R3-20260826","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/AOG.0000000000002090","article-title":"Clinical validation of a test for the diagnosis of vaginitis","volume":"130","author":"Gaydos","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R4-20260826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"R5-20260826","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/cid\/ciaa260","article-title":"Diagnosis and treatment of vaginal discharge syndromes in community practice settings","volume":"72","author":"Hillier","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R6-20260826","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0277-9536(02)00092-8","article-title":"The vaginitis monologues: women's experiences of vaginal complaints in a primary care setting","volume":"56","author":"Karasz","year":"2003","journal-title":"Soc Sci Med"},{"key":"R7-20260826","doi-asserted-by":"crossref","first-page":"e74378","DOI":"10.1371\/journal.pone.0074378","article-title":"The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis","volume":"8","author":"Bilardi","year":"2013","journal-title":"PLoS One"},{"key":"R8-20260826","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/AOG.0b013e31820b07d5","article-title":"Alternative therapies in women with chronic vaginitis","volume":"117","author":"Nyirjesy","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R9-20260826","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0029-7844(97)00242-1","article-title":"Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms","volume":"90","author":"Nyirjesy","year":"1997","journal-title":"Obstet Gynecol"},{"key":"R10-20260826","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/archinte.1990.00390200111021","article-title":"The limited value of symptoms and signs in the diagnosis of vaginal infections","volume":"150","author":"Schaaf","year":"1990","journal-title":"Arch Intern Med"},{"key":"R11-20260826","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.291.11.1368","article-title":"Evaluation of vaginal complaints","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"R12-20260826","doi-asserted-by":"crossref","first-page":"769950","DOI":"10.3389\/fcimb.2021.769950","article-title":"The effect of gender-affirming medical care on the vaginal and neovaginal microbiomes of transgender and gender-diverse people","volume":"11","author":"Krakowsky","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"R13-20260826","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/OLQ.0000000000000972","article-title":"High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis","volume":"46","author":"Peebles","year":"2019","journal-title":"Sex Transm Dis"},{"key":"R14-20260826","first-page":"413","article-title":"Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis","volume":"95","author":"Giraldo","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R15-20260826","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1128\/JCM.02485-07","article-title":"Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection","volume":"46","author":"Vermitsky","year":"2008","journal-title":"J Clin Microbiol"},{"key":"R16-20260826","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11908-010-0137-9","article-title":"Vulvovaginal candidiasis caused by non-albicans Candida species: new insights","volume":"12","author":"Kennedy","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"R17-20260826","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3109\/1040841X.2015.1091805","article-title":"Vulvovaginal candidiasis: epidemiology, microbiology and risk factors","volume":"42","author":"Goncalves","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"R18-20260826","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0002-9378(98)80001-X","article-title":"Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations","volume":"178","author":"Sobel","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"R19-20260826","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/cid\/ciy079","article-title":"Prevalence and correlates of Trichomonas vaginalis infection among men and women in the United States","volume":"67","author":"Patel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R20-20260826","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/OLQ.0b013e318286bb53","article-title":"Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008","volume":"40","author":"Satterwhite","year":"2013","journal-title":"Sex Transm Dis"},{"key":"R21-20260826","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/OLQ.0000000000001383","article-title":"Incidence and prevalence of Trichomonas vaginalis infection among persons aged 15 to 59 years: United States, 2018","volume":"48","author":"Lewis","year":"2021","journal-title":"Sex Transm Dis"},{"key":"R22-20260826","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/OLQ.0000000000000038","article-title":"Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence","volume":"40","author":"Meites","year":"2013","journal-title":"Sex Transm Dis"},{"key":"R23-20260826","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/OLQ.0000000000001038","article-title":"Prevalence and correlates of Trichomonas vaginalis infection using the OSOM rapid point-of-care test among women attending New York City sexual health clinics, May-July 2016","volume":"46","author":"Fallon","year":"2019","journal-title":"Sex Transm Dis"},{"key":"R24-20260826","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1071\/SH22009","article-title":"Burden of trichomoniasis among older adults in the United States: a systematic review","volume":"19","author":"Lindrose","year":"2022","journal-title":"Sex Health"},{"key":"R25-20260826","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/AOG.0000000000004592","article-title":"Performance of a vaginal panel assay compared with the clinical diagnosis of vaginitis","volume":"138","author":"Broache","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R26-20260826","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/AOG.0000000000005529","article-title":"A comparison of newer and traditional approaches to diagnosing vaginal infections","volume":"143","author":"Powell","year":"2024","journal-title":"Obstet Gynecol"},{"key":"R27-20260826","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/jdv.15146","article-title":"Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? A position statement from the European STI Guidelines Editorial Board","volume":"32","author":"Horner","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R28-20260826","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/cid\/ciab061","article-title":"Are Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum associated with specific genital symptoms and clinical signs in nonpregnant women?","volume":"73","author":"Plummer","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R29-20260826","first-page":"277","article-title":"The clinical indications for testing women for Mycoplasma genitalium","volume":"98","author":"Latimer","year":"2022","journal-title":"Sex Transm Infect"},{"key":"R30-20260826","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMra1808418","article-title":"Bacterial vaginosis and desquamative inflammatory vaginitis","volume":"379","author":"Paavonen","year":"2018","journal-title":"N Engl J Med"},{"key":"R31-20260826","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0002-9378(94)90135-X","article-title":"Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy","volume":"171","author":"Sobel","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"R32-20260826","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11908-010-0135-y","article-title":"Clinical spectrum of desquamative inflammatory vaginitis","volume":"12","author":"Stockdale","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"R33-20260826","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1471-0528.2002.00432.x","article-title":"Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis","volume":"109","author":"Donders","year":"2002","journal-title":"BJOG"},{"key":"R34-20260826","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"R35-20260826","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jsm.12190","article-title":"Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey","volume":"10","author":"Kingsberg","year":"2013","journal-title":"J Sex Med"},{"key":"R36-20260826","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal Health: Insights, Views & Attitudes (VIVA)\u2013results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"key":"R37-20260826","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/GME.0000000000002263","article-title":"Relationships between the vaginal microbiota and genitourinary syndrome of menopause symptoms in postmenopausal women: the Study of Women's Health Across the Nation","volume":"30","author":"Waetjen","year":"2023","journal-title":"Menopause"},{"issue":"suppl 2","key":"R38-20260826","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1086\/516221","article-title":"Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy","volume":"25","author":"Hillier","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R39-20260826","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/infdis\/jiaa675","article-title":"Bacterial communities associated with abnormal Nugent score in postmenopausal versus premenopausal women","volume":"223","author":"Mitchell","year":"2021","journal-title":"J Infect Dis"},{"key":"R40-20260826","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/AOG.0000000000001359","article-title":"2015 ISSVD, ISSWSH and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia","volume":"127","author":"Bornstein","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R41-20260826","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/j.esxm.2016.06.003","article-title":"What do patients want? A needs assessment of vulvodynia patients attending a vulvar diseases clinic","volume":"4","author":"LePage","year":"2016","journal-title":"Sex Med"},{"key":"R42-20260826","first-page":"82","article-title":"A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia?","volume":"58","author":"Harlow","year":"2003","journal-title":"J Am Med Womens Assoc (1972)"},{"key":"R43-20260826","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0002-9378(12)90736-X","article-title":"Cytolytic vaginosis","volume":"165","author":"Cibley","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"R44-20260826","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11908-020-00735-w","article-title":"Cytolytic vaginosis: a critical appraisal of a controversial condition","volume":"22","author":"Voytik","year":"2020","journal-title":"Curr Infect Dis Rep"},{"key":"R45-20260826","doi-asserted-by":"crossref","first-page":"e0280954","DOI":"10.1371\/journal.pone.0280954","article-title":"Scoping review of cytolytic vaginosis literature","volume":"18","author":"Kraut","year":"2023","journal-title":"PLoS One"},{"key":"R46-20260826","first-page":"60","article-title":"Comparative study on vaginal or oral treatment of bacterial vaginosis","volume":"43","author":"Mikamo","year":"1997","journal-title":"Chemotherapy"},{"key":"R47-20260826","first-page":"144","article-title":"Comparison of oral and vaginal metronidazole therapy for nonspecific bacterial vaginosis","volume":"21","author":"Bistoletti","year":"1986","journal-title":"Gynecol Obstet Invest"},{"key":"R48-20260826","doi-asserted-by":"crossref","first-page":"705692","DOI":"10.1155\/2010\/705692","article-title":"Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole","volume":"2010","author":"Bohbot","year":"2010","journal-title":"Infect Dis Obstet Gynecol"},{"key":"R49-20260826","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejogrb.2008.07.022","article-title":"Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects","volume":"141","author":"Brandt","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R50-20260826","first-page":"889","article-title":"Metronidazole for bacterial vaginosis: a comparison of vaginal gel vs. oral therapy","volume":"45","author":"Hanson","year":"2000","journal-title":"J Reprod Med"},{"key":"R51-20260826","first-page":"1020","article-title":"Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole","volume":"79","author":"Schmitt","year":"1992","journal-title":"Obstet Gynecol"},{"key":"R52-20260826","first-page":"256","article-title":"Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial","volume":"96","author":"Paavonen","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R53-20260826","first-page":"799","article-title":"Clindamycin versus metronidazole in the treatment of bacterial vaginosis","volume":"72","author":"Greaves","year":"1988","journal-title":"Obstet Gynecol"},{"issue":"suppl 2","key":"R54-20260826","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1093\/cid\/ciac021","article-title":"Diagnosis and management of bacterial vaginosis: summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention sexually transmitted infections treatment guidelines","volume":"74","author":"Muzny","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R55-20260826","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/OLQ.0000000000001555","article-title":"Evaluating the efficacy of eradicating Gardnerella vaginalis (GV) vaginal colonization with amoxicillin; a randomized, double-blind, phase 2 study","volume":"49","author":"McNeil","year":"2022","journal-title":"Sex Transm Dis"},{"key":"R56-20260826","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1086\/509577","article-title":"A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis","volume":"44","author":"Schwebke","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R57-20260826","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/00016349309021137","article-title":"Erythromycin versus metronidazole in the treatment of bacterial vaginosis","volume":"72","author":"Wathne","year":"1993","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R58-20260826","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/OLQ.0b013e3181af6cfd","article-title":"The efficacy of retreatment with the same medication for early treatment failure of bacterial vaginosis","volume":"36","author":"Bunge","year":"2009","journal-title":"Sex Transm Dis"},{"key":"R59-20260826","doi-asserted-by":"crossref","first-page":"e80074","DOI":"10.1371\/journal.pone.0080074","article-title":"Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota","volume":"8","author":"O'Hanlon","year":"2013","journal-title":"PLoS One"},{"key":"R60-20260826","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12905-023-02303-5","article-title":"Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial","volume":"23","author":"Ross","year":"2023","journal-title":"BMC Womens Health"},{"key":"R61-20260826","doi-asserted-by":"crossref","first-page":"e34540","DOI":"10.1371\/journal.pone.0034540","article-title":"Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial","volume":"7","author":"Bradshaw","year":"2012","journal-title":"PLoS One"},{"key":"R62-20260826","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/1471-0528.16430","article-title":"Sex is associated with the persistence of non-optimal vaginal microbiota following treatment for bacterial vaginosis: a prospective cohort study","volume":"128","author":"Ratten","year":"2021","journal-title":"BJOG"},{"key":"R63-20260826","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1093\/cid\/ciaa1903","article-title":"Treatment of male sexual partners of women with bacterial vaginosis (BV): a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Schwebke","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R64-20260826","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1915254","article-title":"Randomized trial of LACTIN-V to prevent recurrence of bacterial vaginosis","volume":"382","author":"Cohen","year":"2020","journal-title":"N Engl J Med"},{"key":"R65-20260826","doi-asserted-by":"crossref","first-page":"211.e1","DOI":"10.1016\/j.ajog.2010.10.898","article-title":"Tinidazole vs metronidazole for the treatment of bacterial vaginosis","volume":"204","author":"Schwebke","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"R66-20260826","doi-asserted-by":"crossref","first-page":"479.e1","DOI":"10.1016\/j.ajog.2014.06.023","article-title":"A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis","volume":"211","author":"Turner","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"R67-20260826","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1086\/503780","article-title":"High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence","volume":"193","author":"Bradshaw","year":"2006","journal-title":"J Infect Dis"},{"key":"R68-20260826","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1098-0997(1996)4:2<66::AID-IDOG4>3.0.CO;2-5","article-title":"Comparative study of intravaginal metronidazole and triple-sulfa therapy for bacterial vaginosis","volume":"4","author":"Sobel","year":"1996","journal-title":"Infect Dis Obstet Gynecol"},{"key":"R69-20260826","first-page":"388","article-title":"Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial","volume":"69","author":"Boeke","year":"1993","journal-title":"Genitourin Med"},{"key":"R70-20260826","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ajog.2005.11.041","article-title":"Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis","volume":"194","author":"Sobel","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"suppl 2","key":"R71-20260826","first-page":"727","article-title":"Sexually transmitted diseases: treatment guidelines: 1982. U.S. Department of Health and Human Services","volume":"28","year":"1983","journal-title":"J Reprod Med"},{"key":"R72-20260826","first-page":"83","article-title":"Evaluation of metronidazole toxicity: a prospective study","volume":"19","author":"Kapoor","year":"1999","journal-title":"Int J Clin Pharmacol Res"},{"key":"R73-20260826","first-page":"397","article-title":"Therapeutic uses of metronidazole and its side effects: an update","volume":"23","author":"Hernandez Ceruelos","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R74-20260826","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fcimb.2020.00433","article-title":"The microbiome composition of a man's penis predicts incident bacterial vaginosis in his female sex partner with high accuracy","volume":"10","author":"Mehta","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"R75-20260826","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40168-016-0161-6","article-title":"Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis","volume":"4","author":"Zozaya","year":"2016","journal-title":"Microbiome"},{"key":"R76-20260826","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/OLQ.0b013e3182631d89","article-title":"Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women","volume":"39","author":"Mehta","year":"2012","journal-title":"Sex Transm Dis"},{"key":"R77-20260826","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/OLQ.0b013e318214b82d","article-title":"Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: a randomized clinical trial","volume":"38","author":"Bukusi","year":"2011","journal-title":"Sex Transm Dis"},{"key":"R78-20260826","doi-asserted-by":"crossref","first-page":"e0232321","DOI":"10.1128\/mBio.02323-21","article-title":"A prospective, open-label pilot study of concurrent male partner treatment for bacterial vaginosis","volume":"12","author":"Plummer","year":"2021","journal-title":"mBio"},{"key":"R79-20260826","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jit664","article-title":"The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study","volume":"209","author":"Bradshaw","year":"2014","journal-title":"J Infect Dis"},{"key":"R80-20260826","doi-asserted-by":"crossref","first-page":"e0141905","DOI":"10.1371\/journal.pone.0141905","article-title":"Factors associated with bacterial vaginosis among women who have sex with women: a systematic review","volume":"10","author":"Forcey","year":"2015","journal-title":"PLoS One"},{"key":"R81-20260826","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/cid\/ciu1130","article-title":"Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV","volume":"60","author":"Vodstrcil","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R82-20260826","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12905-023-02236-z","article-title":"Impact of (recurrent) bacterial vaginosis on quality of life and the need for accessible alternative treatments","volume":"23","author":"Chow","year":"2023","journal-title":"BMC Womens Health"},{"key":"R83-20260826","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/OLQ.0000000000001420","article-title":"Recurrent bacterial vaginosis: an unmet therapeutic challenge: experience with a combination pharmacotherapy long-term suppressive regimen","volume":"48","author":"Surapaneni","year":"2021","journal-title":"Sex Transm Dis"},{"key":"R84-20260826","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/cid\/ciy554","article-title":"Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial","volume":"68","author":"Marrazzo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R85-20260826","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1097\/OLQ.0000000000001562","article-title":"Data on safety of intravaginal boric acid use in pregnant and nonpregnant women: a narrative review","volume":"48","author":"Mittelstaedt","year":"2021","journal-title":"Sex Transm Dis"},{"key":"R86-20260826","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2147\/IDR.S213853","article-title":"Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses","volume":"12","author":"Sobel","year":"2019","journal-title":"Infect Drug Resist"},{"key":"R87-20260826","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000332398","article-title":"A comparison of dequalinium chloride vaginal tablets (Fluomizin\u00ae) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety","volume":"73","author":"Weissenbacher","year":"2012","journal-title":"Gynecol Obstet Invest"},{"key":"R88-20260826","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/OLQ.0000000000001844","article-title":"Sociodemographic and behavioral predictors of recurrent bacterial vaginosis among sexual health clinic patients in New York City from 2014 to 2018","volume":"50","author":"Davis","year":"2023","journal-title":"Sex Transm Dis"},{"key":"R89-20260826","doi-asserted-by":"crossref","first-page":"e73055","DOI":"10.1371\/journal.pone.0073055","article-title":"Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis","volume":"8","author":"Vodstrcil","year":"2013","journal-title":"PLoS One"},{"key":"R90-20260826","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/OLQ.0b013e31823e68fe","article-title":"Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study","volume":"39","author":"Madden","year":"2012","journal-title":"Sex Transm Dis"},{"key":"R91-20260826","doi-asserted-by":"crossref","first-page":"622.e1","DOI":"10.1016\/j.ajog.2018.02.017","article-title":"Impact of contraceptive initiation on vaginal microbiota","volume":"218","author":"Achilles","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R92-20260826","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/ciaa703","article-title":"Elevated risk of bacterial vaginosis among users of the copper intrauterine device: a prospective longitudinal cohort study","volume":"73","author":"Peebles","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R93-20260826","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/antibiotics10080978","article-title":"Comparative effectiveness of treatments for bacterial vaginosis: a network meta-analysis","volume":"10","author":"Munoz-Barreno","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R94-20260826","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00404-020-05821-x","article-title":"Non-antibiotic treatment of bacterial vaginosis-a systematic review","volume":"303","author":"Tidbury","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"R95-20260826","doi-asserted-by":"crossref","first-page":"20230644","DOI":"10.1515\/med-2023-0644","article-title":"Antibiotics therapy combined with probiotics administered intravaginally for the treatment of bacterial vaginosis: a systematic review and meta-analysis","volume":"18","author":"Ma","year":"2023","journal-title":"Open Med (Wars)"},{"key":"R96-20260826","doi-asserted-by":"crossref","first-page":"938838","DOI":"10.3389\/fnut.2022.938838","article-title":"Probiotics, a promising therapy to reduce the recurrence of bacterial vaginosis in women? A systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Chieng","year":"2022","journal-title":"Front Nutr"},{"key":"R97-20260826","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12978-022-01449-z","article-title":"Probiotics are a good choice for the treatment of bacterial vaginosis: a meta-analysis of randomized controlled trial","volume":"19","author":"Chen","year":"2022","journal-title":"Reprod Health"},{"key":"R98-20260826","doi-asserted-by":"crossref","first-page":"111011","DOI":"10.1016\/j.foodres.2022.111011","article-title":"Validation of probiotic species or subspecies identity in commercial probiotic products using high-resolution PCR method based on large-scale genomic analysis","volume":"154","author":"Kim","year":"2022","journal-title":"Food Res Int"},{"key":"R99-20260826","doi-asserted-by":"crossref","first-page":"693973","DOI":"10.3389\/fmicb.2021.693973","article-title":"Spotlight on the compositional quality of probiotic formulations marketed worldwide","volume":"12","author":"Mazzantini","year":"2021","journal-title":"Front Microbiol"},{"key":"R100-20260826","first-page":"CD006289","article-title":"Probiotics for the treatment of bacterial vaginosis","volume":"7","author":"Senok","year":"2009","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R101-20260826","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-019-0600-6","article-title":"Vaginal microbiome transplantation in women with intractable bacterial vaginosis","volume":"25","author":"Lev-Sagie","year":"2019","journal-title":"Nat Med"},{"key":"R102-20260826","doi-asserted-by":"crossref","first-page":"102070","DOI":"10.1016\/j.eclinm.2023.102070","article-title":"Antibiotic-free vaginal microbiota transplant with donor engraftment, dysbiosis resolution and live birth after recurrent pregnancy loss: a proof of concept case study","volume":"61","author":"Wr\u00f8nding","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R103-20260826","doi-asserted-by":"crossref","first-page":"17948","DOI":"10.1038\/s41598-022-22873-y","article-title":"Screening and characterization of vaginal fluid donations for vaginal microbiota transplantation","volume":"12","author":"Yockey","year":"2022","journal-title":"Sci Rep"},{"key":"R104-20260826","doi-asserted-by":"crossref","first-page":"e0267866","DOI":"10.1371\/journal.pone.0267866","article-title":"Possible misdiagnosis, inappropriate empiric treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis\u2013United States, 2018","volume":"17","author":"Benedict","year":"2022","journal-title":"PLoS One"},{"key":"R105-20260826","article-title":"Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)","author":"Denison","year":"2020","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"suppl_2","key":"R106-20260826","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/ciab1057","article-title":"Vulvovaginal candidiasis: a review of the evidence for the 2021 Centers for Disease Control and Prevention of sexually transmitted infections treatment guidelines","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R107-20260826","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.2015.17844","article-title":"Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth","volume":"315","author":"M\u00f8lgaard-Nielsen","year":"2016","journal-title":"JAMA"},{"key":"R108-20260826","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"key":"R109-20260826","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R110-20260826","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/cid\/ciab841","article-title":"Phase 2 randomized study of oral ibrexafungerp versus fluconazole in vulvovaginal candidiasis","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R111-20260826","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1358\/dot.2022.58.4.3381586","article-title":"Ibrexafungerp for the treatment of vulvovaginal candidiasis","volume":"58","author":"Sobel","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"R112-20260826","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/LGT.0000000000000496","article-title":"Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans","volume":"24","author":"Collins","year":"2020","journal-title":"J Lower Genital Tract Dis"},{"key":"R113-20260826","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/myc.13582","article-title":"A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates","volume":"66","author":"Sobel","year":"2023","journal-title":"Mycoses"},{"key":"R114-20260826","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa033114","article-title":"Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis","volume":"351","author":"Sobel","year":"2004","journal-title":"N Engl J Med"},{"key":"R115-20260826","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1468-3083.2010.03721.x","article-title":"Genital candidosis in heterosexual couples","volume":"25","author":"Lisboa","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R116-20260826","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/sextrans-2013-051361","article-title":"Lack of evidence for sexual transmission of genital Candida species among women who have sex with women: a mixed methods study","volume":"90","author":"Muzny","year":"2014","journal-title":"Sex Transm Infect"},{"key":"R117-20260826","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1097\/QAD.0b013e32836290b6","article-title":"Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission","volume":"27","author":"van de Wijgert","year":"2013","journal-title":"AIDS"},{"key":"R118-20260826","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00404-016-4172-0","article-title":"The effect of contraceptive methods on reproductive tract infections risk: a cross-sectional study having a sample of 52,481 women","volume":"294","author":"Wang","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"R119-20260826","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/13625187.2014.900532","article-title":"The impact of copper-containing and levonorgestrel-releasing intrauterine contraceptives on cervicovaginal cytology and microbiological flora: a prospective study","volume":"19","author":"Erol","year":"2014","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R120-20260826","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1089\/jwh.2010.2708","article-title":"Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence","volume":"20","author":"Iavazzo","year":"2011","journal-title":"J Womens Health (Larchmt)"},{"key":"R121-20260826","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/LGT.0000000000000733","article-title":"Fluconazole-resistant Candida albicans vaginal infections at a referral center and treated with boric acid","volume":"27","author":"File","year":"2023","journal-title":"J Lower Genital Tract Dis"},{"key":"R122-20260826","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1067\/S0002-9378(03)00726-9","article-title":"Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine","volume":"189","author":"Sobel","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R123-20260826","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","article-title":"Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis","volume":"29","author":"Azie","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"R124-20260826","doi-asserted-by":"crossref","first-page":"906563","DOI":"10.3389\/fcimb.2022.906563","article-title":"In vitro antifungal activity of ibrexafungerp (SCY-078) against contemporary blood isolates from medically relevant species of Candida: a European study","volume":"12","author":"Quindos","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R125-20260826","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1128\/JCM.43.5.2155-2162.2005","article-title":"Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases","volume":"43","author":"Richter","year":"2005","journal-title":"J Clin Microbiol"},{"key":"R126-20260826","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/1098-0997(2000)8:5<240::AID-IDOG1026>3.0.CO;2-4","article-title":"Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis","volume":"8","author":"Sood","year":"2000","journal-title":"Infect Dis Obstet Gynecol"},{"key":"R127-20260826","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/sti.2009.040386","article-title":"Prevalence and management of non-albicans vaginal candidiasis","volume":"86","author":"Hettiarachchi","year":"2010","journal-title":"Sex Transm Infect"},{"key":"R128-20260826","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/sti.77.3.212","article-title":"Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections","volume":"77","author":"White","year":"2001","journal-title":"Sex Transm Infect"},{"key":"R129-20260826","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11046-008-9119-y","article-title":"Two cases of vaginitis caused by itraconazole-resistant Saccharomyces cerevisiae and a review of recently published studies","volume":"166","author":"Savini","year":"2008","journal-title":"Mycopathologia"},{"key":"R130-20260826","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/clinids\/16.1.93","article-title":"Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy","volume":"16","author":"Sobel","year":"1993","journal-title":"Clin Infect Dis"},{"key":"R131-20260826","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.2174\/0929867330666230220130024","article-title":"Oteseconazole: first approved orally bioavailable and selective CYP51 inhibitor for the treatment of patients with recurrent vulvovaginal candidiasis","volume":"30","author":"De","year":"2023","journal-title":"Curr Med Chem"},{"key":"R132-20260826","doi-asserted-by":"crossref","first-page":"880.e1","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"R133-20260826","doi-asserted-by":"crossref","first-page":"e00341-19","DOI":"10.1128\/AAC.00341-19","article-title":"In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R134-20260826","doi-asserted-by":"crossref","first-page":"e01817-16","DOI":"10.1128\/AAC.01817-16","article-title":"Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. Krusei isolates clinically resistant to azole and echinocandin antifungal compounds","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R135-20260826","first-page":"918","article-title":"In vitro activities of the tetrazole VT-1161 compared with itraconazole and fluconazole against Cryptococcus and non-albicans Candida species","volume":"113","author":"Wang","year":"2021","journal-title":"Mycologia"},{"key":"R137-20260826","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1128\/AAC.05025-11","article-title":"Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use","volume":"56","author":"Danby","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R138-20260826","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/LGT.0000000000000383","article-title":"Reduced antifungal susceptibility of vulvovaginal Candida species at normal vaginal pH levels: clinical implications","volume":"22","author":"Spitzer","year":"2018","journal-title":"J Lower Genital Tract Dis"},{"key":"R139-20260826","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/14656566.2018.1476490","article-title":"Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species","volume":"19","author":"Sobel","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"R140-20260826","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/107662900419474","article-title":"Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis","volume":"6","author":"Cross","year":"2000","journal-title":"Microb Drug Resist"},{"key":"R141-20260826","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.12669\/pjms.38.8.5984","article-title":"Azoles resistance of Candida species causing vulvo-vaginitis in reproductive age women at a tertiary care setting","volume":"38","author":"Zaman","year":"2022","journal-title":"Pak J Med Sci"},{"key":"R142-20260826","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11046-014-9827-4","article-title":"Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis","volume":"179","author":"Fan","year":"2015","journal-title":"Mycopathologia"},{"key":"R143-20260826","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2340\/00015555-1194","article-title":"Efficacy of fluconazole and nystatin in the treatment of vaginal Candida species","volume":"92","author":"Martins","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"R144-20260826","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000225","article-title":"Topical treatment for vaginal candidiasis (thrush) in pregnancy","author":"Young","year":"2001","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R145-20260826","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.mycmed.2014.05.001","article-title":"In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents","volume":"24","author":"Choukri","year":"2014","journal-title":"J Mycol Med"},{"key":"R146-20260826","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1439-0507.2010.01887.x","article-title":"In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis","volume":"54","author":"Fan","year":"2011","journal-title":"Mycoses"},{"key":"R147-20260826","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1080\/01443615.2022.2035336","article-title":"Effect of intravaginal gentian violet for acute vaginal candidiasis treated with a single dose oral fluconazole: a randomised controlled trial","volume":"42","author":"Chayachinda","year":"2022","journal-title":"J Obstet Gynaecol"},{"key":"R148-20260826","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00003081-199906000-00004","article-title":"Current evaluation and management of vulvovaginitis","volume":"42","author":"Haefner","year":"1999","journal-title":"Clin Obstet Gynecol"},{"key":"R149-20260826","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/LGT.0000000000000473","article-title":"CD101 topical compared with oral fluconazole for acute vulvovaginal candidiasis: a randomized controlled trial","volume":"23","author":"Nyirjesy","year":"2019","journal-title":"J Lower Genital Tract Dis"},{"key":"R150-20260826","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/599213","article-title":"Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis","volume":"199","author":"McClelland","year":"2009","journal-title":"J Infect Dis"},{"key":"R151-20260826","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/sti.2008.035451","article-title":"Prospective study of correlates of vaginal Lactobacillus colonization among high-risk HIV-1 seronegative women","volume":"85","author":"Baeten","year":"2009","journal-title":"Sex Transm Infect"},{"key":"R152-20260826","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/OLQ.0000000000001066","article-title":"The vaginal microbiota and behavioral factors associated with genital Candida albicans detection in reproductive-age women","volume":"46","author":"Brown","year":"2019","journal-title":"Sex Transm Dis"},{"key":"R153-20260826","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0002-9378(98)80028-8","article-title":"Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy","volume":"178","author":"Cotch","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"R154-20260826","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2019.10.008","article-title":"Associations between the vaginal microbiome and Candida colonization in women of reproductive age","volume":"222","author":"Tortelli","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"R155-20260826","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1038\/s41467-021-26390-w","article-title":"A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase","volume":"12","author":"MacAlpine","year":"2021","journal-title":"Nat Commun"},{"key":"R156-20260826","doi-asserted-by":"crossref","first-page":"1832832","DOI":"10.1080\/20002297.2020.1832832","article-title":"Lactobacillus rhamnosus strains of oral and vaginal origin show strong antifungal activity in vitro","volume":"12","author":"Rose J\u00f8rgensen","year":"2020","journal-title":"J Oral Microbiol"},{"key":"R157-20260826","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/1471-0528.15870","article-title":"Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs","volume":"127","author":"van de Wijgert","year":"2020","journal-title":"BJOG"},{"key":"R158-20260826","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010496.pub2","article-title":"Probiotics for vulvovaginal candidiasis in non-pregnant women","author":"Xie","year":"2017","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R159-20260826","doi-asserted-by":"crossref","first-page":"e12970","DOI":"10.1111\/dth.12970","article-title":"Probiotics for oral and vulvovaginal candidiasis: a review","volume":"32","author":"Shenoy","year":"2019","journal-title":"Dermatol Ther"},{"key":"R160-20260826","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/QAI.0b013e3181eda955","article-title":"A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women","volume":"55","author":"Kissinger","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R161-20260826","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S1473-3099(18)30423-7","article-title":"Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial","volume":"18","author":"Kissinger","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R162-20260826","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/OLQ.0000000000001574","article-title":"A comparison of single-dose versus multidose metronidazole by select clinical factors for the treatment of Trichomonas vaginalis in women","volume":"49","author":"Muzny","year":"2022","journal-title":"Sex Transm Dis"},{"key":"R163-20260826","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.sxmr.2021.12.004","article-title":"Secnidazole for trichomoniasis in women and men","volume":"10","author":"Muzny","year":"2022","journal-title":"Sex Med Rev"},{"issue":"suppl_2","key":"R164-20260826","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/cid\/ciac030","article-title":"Diagnosis and management of Trichomonas vaginalis: summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention sexually transmitted infections treatment guidelines","volume":"74","author":"Kissinger","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R165-20260826","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11908-019-0687-4","article-title":"Management of resistant trichomoniasis","volume":"21","author":"Alessio","year":"2019","journal-title":"Curr Infect Dis Rep"},{"key":"R166-20260826","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/OLQ.0000000000001741","article-title":"Successful treatment of persistent 5-nitroimidazole-resistant trichomoniasis with an extended course of oral secnidazole plus intravaginal boric acid","volume":"50","author":"McNeil","year":"2023","journal-title":"Sex Transm Dis"},{"key":"R167-20260826","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamainternmed.2018.7241","article-title":"Nitroimidazole resistance in Trichomonas vaginalis infection: a teachable moment","volume":"179","author":"Salas","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R168-20260826","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/OLQ.0000000000000903","article-title":"Metronidazole-resistant trichomoniasis: beneficial pharmacodynamic relationship with high-dose oral tinidazole and vaginal paromomycin combination therapy","volume":"46","author":"Henien","year":"2019","journal-title":"Sex Transm Dis"},{"key":"R169-20260826","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/OLQ.0b013e31822037e4","article-title":"Resistant trichomoniasis: successful treatment with combination therapy","volume":"38","author":"Nyirjesy","year":"2011","journal-title":"Sex Transm Dis"},{"key":"R170-20260826","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/OLQ.0000000000001801","article-title":"Multidrug-resistant trichomoniasis: successful treatment with 3 months of twice-daily intravaginal boric acid","volume":"50","author":"Seyedroudbari","year":"2023","journal-title":"Sex Transm Dis"},{"key":"R171-20260826","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/AOG.0b013e3182117c9e","article-title":"Prognosis and treatment of desquamative inflammatory vaginitis","volume":"117","author":"Sobel","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R172-20260826","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"},{"key":"R173-20260826","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000003944","article-title":"Diagnosis and management of vulvar skin disorders. ACOG Practice Bulletin No. 224. American College of Obstetricians and Gynecologists","volume":"136","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R174-20260826","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/IJWH.S436222","article-title":"Multimodal and interdisciplinary interventions for the treatment of localized provoked vulvodynia: a scoping review of the literature from 2010 to 2023","volume":"16","author":"Rains","year":"2024","journal-title":"Int J Womens Health"}],"updated-by":[{"DOI":"10.1097\/aog.0000000000005975","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000}}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:03:29Z","timestamp":1787742209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":173,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005673","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"2024-02-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}